Yair Herishanu
A5016426595- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Advanced Breast Cancer Therapies
- Acute Myeloid Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Medical Imaging Techniques and Applications
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Acute Lymphoblastic Leukemia research
- Galectins and Cancer Biology
- Blood disorders and treatments
- Cutaneous lymphoproliferative disorders research
- Calcium signaling and nucleotide metabolism
- Protein Degradation and Inhibitors
- Autoimmune Bullous Skin Diseases
- Neutropenia and Cancer Infections
Tel Aviv University
2016-2025
Tel Aviv Sourasky Medical Center
2015-2024
Centre for Research and Technology Hellas
2023
National and Kapodistrian University of Athens
2023
Kaplan Medical Center
2018
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study characterize course COVID-19 in and identify potential predictors outcome. Of 190 confirmed diagnosed between 28/03/2020 22/05/2020, 151 (79%) presented (need oxygen and/or intensive care admission). Severe was associated advanced...
BackgroundMost patients with chronic lymphocytic leukaemia progress after treatment or retreatment targeted therapy chemoimmunotherapy and have limited subsequent options. Response levels to the single-agent venetoclax in relapsed setting is unknown. We aimed assess activity without previous B-cell receptor-associated kinase inhibitor (BCRi) treatment.MethodsThis multicentre, open-label, single-arm, phase 3b trial (VENICE-1) assessed safety of monotherapy adults refractory leukaemia,...
Summary Multiple myeloma (MM) patients are at excess risk for clinically significant COVID19 infection. BNT162b2 mRNA (BNT162b2) vaccine provides effective protection against the general population, yet its effect in MM may be compromised due to disease and therapy‐related factors was not evaluated. This single‐centre prospective study included tested serological response 14–21 days post second vaccine. Vaccinated healthy volunteers served as controls. In all, 171 patients, median age 70...
Summary Background Invasive fungal diseases (IFD) are life‐threatening infections most commonly diagnosed in acute leukaemia patients with prolonged neutropenia and uncommonly lymphoproliferative diseases. Objectives Following the initial report of aspergillosis shortly after beginning ibrutinib for chronic lymphocytic leukaemia, a survey was developed to seek additional cases IFD during treatment. Methods Local international physicians groups were approached relevant cases. Patients...
Data regarding efficacy and toxicity of chimeric antigen receptor T (CAR-T) cell therapy in the elderly, geriatric population are insufficient. In 2019, tisagenlecleucel axicabtagene-ciloleucel were commercially approved for relapsed/refractory diffuse large B-cell lymphoma. From May 2019 onwards, 47 Bcell lymphoma patients, ≥70 years underwent lymphopharesis three Israeli centers. Elderly (n=41, mean age 76.2 years) young 55.4 patients matched based on ECOG performance status lactose...
Electrophiles for covalent inhibitors that are suitable in vivo administration rare. While acrylamides prevalent FDA-approved drugs, chloroacetamides considered too reactive such purposes. We report sulfamate-based electrophiles maintain chloroacetamide-like geometry with tunable reactivity. In the context of BTK inhibitor ibrutinib, sulfamate analogues showed low reactivity comparable potency protein labeling, vitro, and cellular kinase activity assays were effective a mouse model CLL....
Abstract Lasting B cell persistence depends on survival signals that are transduced by surface receptors. In this study, we describe a novel biological mechanism essential for and homeostasis of normal peripheral mature cells chronic lymphocytic leukemia cells, regulated the heparin-binding cytokine, midkine (MK), its proteoglycan receptor, receptor-type tyrosine phosphatase ζ (RPTPζ). We demonstrate MK initiates signaling cascade leading to binding RPTPζ. mice lacking PTPRZ, proportion...
Chronic lymphocytic leukemia (CLL) is characterized by clonal proliferation and progressive accumulation of mature B lymphocytes in the peripheral blood, lymphoid tissues, bone marrow. CLL profound immune defects leading to severe infectious complications. T cells are numerically, phenotypically, functionally highly abnormal CLL, with only limited ability exert antitumor responses. Exhaustion has also been suggested play an important role CLL-mediated cell exhaustion achieved aberrant...
Abstract In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) related disorders (small lymphoma high‐count monoclonal B lymphocytosis) infected by SARS‐CoV‐2, including development post‐COVID condition. Data from 1540 CLL SARS‐CoV‐2 January 2020 to May 2022 were included in analysis assigned four phases based on cases disposition variants emergence. Post‐COVID condition was defined...
An insect-bite-like reaction is known to occur in patients with chronic lymphocytic leukemia (CLL). Most of the literature, however, consists isolated case reports or small series. The aim this retrospective study was review national experience a large group CLL. cohort these skin reactions consisted 48 (25 males, 23 females) mean age 64.8 yr (range 33-89) at eruption. Data on clinical, histologic, immunophenotypic, and cytogenetic characteristics, treatment, outcome were collected from...
The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective examined the and safety administered real life settings. Forty-seven patients, 31 with de-novo DLBCL 16 transformed lymphoma, treated polatuzumab-based regimen 14 Israeli centers between June 2018 November 2019, were included. Median age was 66.1 years (60.4–78.8) median number prior lines 3 (2–7). overall response rate 61% (n = 29), including...